Q2 FY27 revenue up 9.9%; FY28 turnover target of INR700 crore reaffirmed
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.3 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 income grew 9.9% year on year to INR1,149 million; operating profit rose 10.5% to INR408 million, a 35.5% margin, and net profit was INR206 million. H1 income was INR2,278 million. Vimta is debt-free with INR701 million cash and an INR80 crore FY27 spending plan. Biologics revenue began. Management reaffirmed FY28 turnover of INR700 crore with a 35-36% operating margin, flagging a possible 1 to 2 percentage point medium-term dip.
Reaffirmed FY28 targets and steady profit growth are positive, but slower sales and possible margin pressure could cap near-term gains.